Premium
Haemophilia A management in Victorian, New South Wales and South Australian haemophilia centres
Author(s) -
Ekert Henry,
Ekert Nicole L,
Street Alison M,
Rickard Kevin A,
McPherson V Jean,
Toogood Ian R G,
Lloyd John V
Publication year - 1995
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1995.tb138544.x
Subject(s) - haemophilia , medicine , haemophilia a , economic shortage , per capita , haemophilia b , per capita income , pediatrics , demography , surgery , environmental health , population , linguistics , philosophy , pathology , government (linguistics) , sociology
Objective To examine the management of haemophilia A in Australia and to compare it with international trends. Methods Six haemophilia centres treating most patients in Victoria, New South Wales and South Australia were surveyed in 1993 by means of a written questionnaire followed by an “on site” interview. Results The centres were treating 739 patients; 234 (32%) had severe haemophilia. Factor VIII inhibitors were present in 5.9% of all patients and in 19% of those with severe disease. Twenty‐three per cent were human immunodeficiency virus (HIV) antibody‐positive and 74% were hepatitis C virus (HCV) antibody‐positive. The main treatment was “on demand” therapy for acute bleeds (average use of factor VIII: 1350 IU/kg per year for children; and 780 IU/kg per year for adults). Prophylactic therapy was used in only 17 patients, with doses of 3000–4500 IU/kg per year. One million IU was used for three patients with high litre inhibitors who had “tolerising” therapy. While most developed countries have a factor VIII supply of 2–5 IU per capita, the total supplied to the States represented 1.46 IU per capita, while use at the centres represented 1.1 IU per capita. Conclusion Because supply of factor VIII is limited, use was less than half that recommended internationally. Shortage of factor VIII has compromised prophylactic therapy and virtually prevented “tolerising” therapy.